Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trialAndrés Poveda, Nicolas Pécuchet, Jacob Korach et al.|The Lancet Oncology|2021Cited by 412
Incidence of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in patients (pts) with a germline (g) <i>BRCA</i> mutation (m) and platinum-sensitive relapsed ovarian cancer (PSR OC) receiving maintenance olaparib in SOLO2: Impact of prior lines of platinum therapy.Jacob Korach, Éric Pujade-Lauraine, Simon Turner et al.|Journal of Clinical Oncology|2018Cited by 17
Analysis of tumour samples from SOLO1: Frequency of BRCA specific loss of heterozygosity (LOH) and progression-free survival (PFS) according to homologous recombination repair deficiency (HRD)-LOH scoreCharlie Gourley, E.A. Harrington, Jessica Brown et al.|Annals of Oncology|2019Cited by 7